Skip to main content

Advertisement

SpringerLink
Log in

Review of gastrointestinal tolerability and safety of Meloxicam

  • Published:
InflammoPharmacology Aims and scope Submit manuscript

Abstract

Selective COX-2 inhibition relative to COX-1 has consistently been demonstrated for meloxicam in various in vitro test systems. In human platelets ex vivo COX-1-dependent thromboxane formation is partially and dose dependently inhibited, however no significant inhibition of platelet aggregation has been observed with the recommended doses of 7.5 mg and 15 mg meloxicam daily. With once daily dosing, meloxicam has demonstrated efficacy in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Meloxicam was granted its first marketing authorization in 1995 and is now available in more than 100 countries. Meloxicam has been studied in clinical trials involving more than 30 000 patients and is estimated to have been prescribed for more than 30 million patients worldwide to date. Clinically, meloxicam offers similar efficacy to recommended doses of well-established nonsteroid anti-inflammatory drugs (NSAIDs), including diclofenac, piroxicam and naproxen. Meloxicam distinguishes itself from established NSAIDs with a reduced risk of certain gastrointestinal adverse events. This has consistently been demonstrated in randomized clinical trials, large scale clinical outcome studies, pooled analyses and meta-analyses. Post-marketing experience is consistent with the safety profile established in these studies and analyses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  • Carrabba, M., Paresce, E., Angelini, M., et al (1995). A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: a single-blind, randomized, multicentre study, Curr. Med. Res. Opin. 13 (6), 343–355.

    Google Scholar 

  • Churchill, L., Graham, A. G., Shih, C. K., et al. (1996). Selective inhibition of human cyclo-oxygenase-2 by meloxicam, Inflammopharmacology 4, 125–135.

    Google Scholar 

  • Degner, F., Sigmund, R. and Zeidler, H. (2000). Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease, Clin. Ther. 22 (4), 400–410.

    Google Scholar 

  • De Meijer, A., Vollaard, H., de Metz, M., et al (1999). Meloxicam 15 mg/day spares platelet function in healthy volunteers, Clin. Pharmacol. Ther. 66, 425–430.

    Google Scholar 

  • Dequeker, J., Hawkey, C., Kahan, A., et al (1998). Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis, Brit. J. Rheumatol. 37 (9), 946–951.

    Google Scholar 

  • Distel, M., Mueller, C. and Bluhmki, E. (1996). Global analysis of gastrointestinal safety of a new NSAID, meloxicam, Inflammopharmacology 4, 71–81.

    Google Scholar 

  • Dougados, M., Gueguen, A., Nakache, J. P., et al (1999). Ankylosing spondylitis: what is the optimumduration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial, Rheumatology 38 (3), 235–244.

    Google Scholar 

  • Engelhardt, G., Homma, D., Schlegel, K., et al (1995). Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-in' ammatory agent with favourable gastrointestinal tolerance, Inflamm. Res. 44, 423–433.

    Google Scholar 

  • Furst, D., Hall, D., Roszko, P. J., et al (2000). Efficacy, Safety and Dose Response of Meloxicam up to 22.5 mg in the treatment of rheumatoid arthritis (RA): Results of a phase III double-blind, placebo controlled trial. ACR 64 th Annual Scientific Meeting, Philadelphia.

  • Ghozlan, P. R., Bernhardt, M., Velicitat, P., et al (1996). Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicamin patients with rheumatoid arthritis or osteoarthritis, Brit. J. Rheumatol. 35 (Suppl. 1), 51–55.

    Google Scholar 

  • Goei The, H. S., Lund, B., Distel, M. R., et al (1997). A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee, Osteoarthritis Cartilage 5 (4), 283–288.

    Google Scholar 

  • Hawkey, C. J. (1999). COX-2 inhibitors, Lancet 353, 307–314.

    Google Scholar 

  • Hawkey, C., Kahan, A., Steinbrück, K., et al. (1998). Gastrointestinal tolerability of meloxicam com-pared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment, Brit. J. Rheumatol. 37 (9), 937–945.

    Google Scholar 

  • Hosie, J., Distel, M. and Bluhmki, E. (1996). Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium, Brit. J. Rheumatol. 35 (Suppl. 1), 39–43.

    Google Scholar 

  • Hosie, J., Distel, M. and Bluhmki, E. (1997). Efficacy and tolerabilityof meloxicamversus piroxicam in patients with osteoarthritisof the hip or knee: a six-month double-blindstudy, Clin. Drug Invest. 13 (4), 175–184.

    Google Scholar 

  • Huskisson, E. C., Narjes, H. and Bluhmki, E. (1994). Efficacy and tolerance of meloxicam, a new NSAID, in daily oral doses of 15, 30 and 60 mg in comparison to 20 mg piroxicamin patients with rheumatoid arthritis, Scand. J. Rheumatol. S98, 115.

    Google Scholar 

  • Lanes, S. F., Garcia Rodriguez, L. A. and Hwang, E. (2000). Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin, Pharmacoepidemiol. Drug Safety 9, 113–117.

    Google Scholar 

  • Lemmel, E. M., Bolten, W., Burgos-Vargas, R., et al. (1997). Efficacy and safety of meloxicam in patients with rheumatoid arthritis, J. Rheumatol. 24, 282–290.

    Google Scholar 

  • Linden, B., Distel, M. and Bluhmki, E. (1996). A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip, Brit. J. Rheumatol. 35 (Suppl. 1), 35–38.

    Google Scholar 

  • Lund, B., Distel, M. and Bluhmki, E. (1998). A double-blind, randomized, placebo-controlledstudy of efficacy and tolerance of meloxicamtreatment in patients with osteoarthritis of the knee, Scand. J. Rheumatol. 27, 32–37.

    Google Scholar 

  • Martin, R. M., Biswas, P. and Mann, R. D. (2000). The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicamuse amongst 19087 patients in general practice in England: cohort study, Brit. J. Clin. Pharmacol. 50, 35–42.

    Google Scholar 

  • Panara, M. R., Renda, G., Sciulli, M. G., et al (1999). Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects, J. Phar-macol. Exp. Ther. 290 (1), 276–280.

    Google Scholar 

  • Patrignani, P., Panara, M. R., Sciulli, M. G., et al. (1997). Differential inhibition of human prostaglandinendoperoxide synthase-1 and-2 by nonsteroidal anti-inflammatory drugs, J. Physiol. Pharmacol. 48, 623–631.

    Google Scholar 

  • Schoenfeld, P. (1999). Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials, Amer. J. Med. 107 (Suppl. 6A), 48S–54S.

    Google Scholar 

  • Silverstein, F. E., Faich, G. F., Goldstein, J. L., et al (2000). Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis, J. Amer. Med. Assn. 284, 1247–1255.

    Google Scholar 

  • Stichtenoth, D. O., Wagner, B. and Frölich, J. C. (1997). Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers, J. Invest. Med. 45, 44–49.

    Google Scholar 

  • Van Hecken, A., Schwartz, J. I., Depre, M., et al. (2000). Comparative inhibitory activity of rofecoxib (MK-0966), meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 vs. COX-1 in healthy volunteers, J. Clin. Pharmacol. 40, 1109–1120.

    Google Scholar 

  • Warner, T., Giuliano, F., Vojnovic, I., et al. (1999). Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2are associated with human gastrointestinaltoxicity: A full in vitro analysis, Proc. Natl. Acad. Sci. USA 96, 7563–7568.

    Google Scholar 

  • Wojtulewski, J. A., Schattenkirchner, M., Barcelo, P., et al. (1996). A six-month double-blind trial to compare the efficacy and safety of meloxicam7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis, Brit. J. Rheumatol. 35 (Suppl. 1), 22–28.

    Google Scholar 

  • Yocum, D., Fleischmann, R., Dalgin, P., et al. (2000). Efficacy and safety of meloxicam in the treatment of osteoarthritis, Arch. Intern. Med. 160, 2947–2954.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Boehringer Ingelheim GmbH, Bingerstr. 173, D-55216 Ingelheim, Germany

    Frank Degner & Bill Richardson

Authors
  1. Frank Degner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bill Richardson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Degner, F., Richardson, B. Review of gastrointestinal tolerability and safety of Meloxicam. Inflammopharmacology 9, 71–80 (2001). https://doi.org/10.1163/156856001300248344

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1163/156856001300248344

Search

Navigation